Welcome to our dedicated page for Maravai Lifesciences Holdings SEC filings (Ticker: MRVI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how Maravai Lifesciences converts its nucleic acid expertise into revenue isn’t easy; each 10-K details proprietary mRNA reagent demand, biologics safety margins and supply-chain dependencies in dense language. Whether you’re searching for “Maravai Lifesciences insider trading Form 4 transactions” after a sudden share move or asking for the “Maravai Lifesciences annual report 10-K simplified,” the sheer volume of data can slow critical decisions. This page offers Maravai Lifesciences SEC filings explained simply.
Stock Titan removes that complexity. Our AI-powered summaries surface the numbers that matter, from customer concentration to R&D milestones, and attach plain-English context to every document. We stream each “Maravai Lifesciences quarterly earnings report 10-Q filing” the moment it hits EDGAR, push “Maravai Lifesciences Form 4 insider transactions real-time” alerts, and connect the dots so you’re understanding Maravai Lifesciences SEC documents with AI, not spreadsheets.
- Side-by-side graphics of nucleic acid production trends
- Automatic flags on “Maravai Lifesciences proxy statement executive compensation” shifts
- “Maravai Lifesciences 8-K material events explained” within minutes of filing
Use these insights to compare quarterly R&D spend, spot “Maravai Lifesciences executive stock transactions Form 4” before product announcements, or dig into “Maravai Lifesciences earnings report filing analysis” to gauge cash flow for future acquisitions. Real-time updates, historical archives and expert notes turn this page into a single, reliable source for every disclosure, so you can act faster and with greater confidence.
Maravai LifeSciences Holdings, Inc. (MRVI) filed an 8-K announcing a Chief Financial Officer transition effective 30 June 2025. The Board appointed Rajesh Asarpota (age 58) as CFO, replacing Kevin Herde, who will remain through 31 January 2026 as a paid consultant to ensure continuity. No family relationships or related-party transactions were reported.
Compensation package: Mr. Asarpota will receive a $550,000 base salary, 70 % target cash bonus, and a $200,000 sign-on bonus (claw-back if he departs within one year without “good reason” or is terminated for “cause”). Equity awards granted on the effective date include (i) 333,333 non-qualified stock options, (ii) 500,000 restricted stock units, and (iii) 750,000 performance stock units tied to stock-price hurdles. Options and RSUs vest 1/3 after one year and monthly thereafter over three years; PSUs cliff-vest based on share-price performance measured before the third anniversary. Equity may accelerate under specified conditions.
Severance terms: On a Qualifying Termination the CFO receives (i) any earned prior bonus, (ii) pro-rated current-year bonus, (iii) one year of base salary plus target bonus paid over 12 months, and (iv) up to 12 months of subsidised health coverage. If termination occurs within 24 months after a change in control, cash severance doubles to two times salary plus bonus, is paid lump-sum, health coverage extends to 24 months, and unvested time-vesting equity fully vests.
Outgoing CFO Kevin Herde will receive benefits under his May 2023 employment agreement upon departure. A press release dated 25 June 2025 (Exhibit 99.1) announced the appointment; the release is furnished, not filed, under Regulation FD. An employment agreement (Exhibit 10.1) and customary indemnification agreement accompany the filing.
Maravai LifeSciences Holdings, Inc. (MRVI) – Form 4 insider filing dated 06/18/2025
Director Benjamin James Daverman reported the acquisition of 89,139 Class A common-stock restricted stock units (RSUs) on 06/16/2025 under the company’s 2020 Omnibus Incentive Plan. The RSUs were recorded at an accounting grant price of $2.16 per share and will vest in full on the earlier of (i) one year from the grant date or (ii) the date of the 2026 annual meeting of stockholders.
Following this grant, Daverman’s reported beneficial ownership rises to 138,055 shares, classified as direct ownership. However, the filing notes that these securities are held for the benefit of a GTCR-affiliated entity; Daverman disclaims any pecuniary interest, a standard practice for partners of private-equity sponsors serving on portfolio-company boards.
No derivative securities were reported in Table II, and there were no dispositions. The transaction was filed by one reporting person, and the box indicating Rule 10b5-1(c) trading-plan activity was not checked, implying the RSU grant was a standard board-compensation award.
Key take-aways for investors:
- The award helps align director incentives with shareholder value through equity compensation.
- Because the shares are RSUs (not an open-market purchase), the grant does not directly signal insider conviction about current valuation.
- The relatively modest share count and beneficial-ownership disclosure are unlikely to materially affect MRVI’s share float or governance structure.
Maravai LifeSciences Holdings (MRVI) – Director Equity Grant
Form 4 filed 06/18/2025 shows director Susannah Gray acquired 89,139 Class A common shares via restricted stock units (RSUs) granted on 06/16/2025 under the 2020 Omnibus Incentive Plan. The RSUs vest fully on the earlier of one year from grant or the 2026 annual stockholders’ meeting and carry a reference price of $2.16 per share.
Following the award, Gray’s direct beneficial ownership rises to 169,907 shares. No dispositions or derivative transactions were reported, and the filing contains no financial or operational data.
The transaction is routine, compensation-related insider acquisition rather than an open-market purchase; therefore, it signals continued alignment of director incentives with shareholders but has limited standalone market impact.
Maravai LifeSciences Holdings, Inc. (MRVI) – Form 4 insider activity
Director Murali K. Prahalad reported the grant of 89,139 Class A common-stock restricted stock units (RSUs) on 16 June 2025 under the company’s 2020 Omnibus Incentive Plan. The transaction was coded “A” (acquired) at a reference price of $2.16 per share. The RSUs vest in full on the earlier of (i) one year from the grant date or (ii) the date of the 2026 annual meeting of stockholders.
Following this equity award, Prahalad’s direct beneficial ownership rises to 154,607 shares. No sales, options, or other derivative positions were reported, and the filing does not reference a Rule 10b5-1 trading plan.
The disclosure reflects routine director compensation rather than an open-market purchase, providing limited immediate valuation insight but modestly increasing insider alignment with shareholders.
Form 4 snapshot: On 18 Jun 2025, Director Sean Laurence Cunningham filed a Form 4 disclosing an equity award from Maravai LifeSciences Holdings, Inc. (ticker MRVI).
Key transaction details: On 16 Jun 2025, Cunningham acquired 89,139 Class A common shares in the form of restricted stock units (RSUs) granted under the company’s 2020 Omnibus Incentive Plan at an indicated price of $2.16 per share. The RSUs vest in full on the earlier of one year from grant or the date of the 2026 annual meeting.
Post-grant ownership: The filing reports 138,055 shares held directly following the award. However, the footnote explains that these shares are held for the benefit of a GTCR-affiliated entity; Cunningham disclaims any pecuniary interest and is therefore not treated as the economic owner for Section 16 purposes.
Nature of the filing: No open-market purchase or sale occurred, and no derivative securities were involved. This is a routine board compensation grant rather than a signaling transaction. The filing does not contain earnings information, strategic announcements, or changes in control.
Form 4 filed for Maravai LifeSciences Holdings, Inc. (MRVI) discloses that director Jessica Hopfield received 89,139 Class A common-stock restricted stock units (RSUs) on 16 June 2025 under the company’s 2020 Omnibus Incentive Plan. The RSUs will vest in full on the earlier of one year from the grant date or the 2026 annual stockholders’ meeting. Following the award, Hopfield now reports 199,907 shares held directly. Transaction code “A” confirms the award was an acquisition, not an open-market purchase or sale. No derivative securities were involved, and there were no dispositions. Overall, the filing represents a routine equity incentive grant aligning director compensation with shareholder interests.
FAQ
What is the current stock price of Maravai Lifesciences Holdings (MRVI)?
What is the market cap of Maravai Lifesciences Holdings (MRVI)?
What is the primary business focus of Maravai Lifesciences?
Which market segments does the company serve?
How does Maravai Lifesciences generate revenue?
What distinguishes Maravai from competitors?
What are the core products offered by Maravai Lifesciences?
How does the company support scientific research?
What role do acquisitions play in Maravai’s business model?
